JAMA Oncology : Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
JAMA Network - Un pódcast de The JAMA Network
Categorías:
Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
